Hunan Er-Kang Pharmaceutical Co., Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 867.81 million compared to CNY 829.67 million a year ago. Revenue was CNY 870.55 million compared to CNY 832.43 million a year ago.

Net income was CNY 30.09 million compared to CNY 93.51 million a year ago. Basic earnings per share from continuing operations was CNY 0.0146 compared to CNY 0.0453 a year ago. Diluted earnings per share from continuing operations was CNY 0.0146 compared to CNY 0.0453 a year ago.